Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;12(10):1522.
doi: 10.3390/biom12101522.

Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1)

Michela Varani  1 , Valeria Bentivoglio  1 , Chiara Lauri  1 , Danilo Ranieri  2 , Alberto Signore  1
Affiliations
Review

Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1)

Michela Varani et al. Biomolecules. .

Abstract

The use of nanoparticles (NPs) is rapidly increasing in nuclear medicine (NM) for diagnostic and therapeutic purposes. Their wide use is due to their chemical-physical characteristics and possibility to deliver several molecules. NPs can be synthetised by organic and/or inorganic materials and they can have different size, shape, chemical composition, and charge. These factors influence their biodistribution, clearance, and targeting ability in vivo. NPs can be designed to encapsulate inside the core or bind to the surface several molecules, including radionuclides, for different clinical applications. Either diagnostic or therapeutic radioactive NPs can be synthetised, making a so-called theragnostic tool. To date, there are several methods for radiolabelling NPs that vary depending on both the physical and chemical properties of the NPs and on the isotope used. In this review, we analysed and compared different methods for radiolabelling NPs for single-photon emission computed tomography (SPECT) use.

Keywords: SPECT/CT; nanoparticles; nanotechnology; nuclear medicine; radiolabelling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different radiolabelling methods of NPs.
See this image and copyright information in PMC

References

    1. Lamb J., Holland J.P. Advanced Methods for Radiolabeling Multimodality Nanomedicines for SPECT/MRI and PET/MRI. J. Nucl. Med. 2018;59:382–389. doi: 10.2967/jnumed.116.187419. - DOI - PubMed
    1. Pellico J., Gawne P.J., de Rosales R.T.M. Radiolabelling of nanomaterials for medical imaging and therapy. Chem. Soc. Rev. 2021;50:3355–3423. - PubMed
    1. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 2008;60:1347–1370. doi: 10.1016/j.addr.2008.04.006. - DOI - PMC - PubMed
    1. Coenen H.H., Gee A.D., Adam M., Antoni G., Cutler C.S., Fujibayashi Y., Jeong J.M., Mach R.H., Mindt T.L., Pike V.W., et al. Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. J. Label. Comp. Radiopharm. 2018;61:402–404. doi: 10.1002/jlcr.3604. - DOI - PubMed
    1. Varani M., Galli F., Auletta S., Signore A. Radiolabelled nanoparticles for cancer diagnosis. Clin. Transl. Imaging. 2018;6:271–292. doi: 10.1007/s40336-018-0283-x. - DOI

Publication types

MeSH terms

LinkOut - more resources